Thromboprophylaxis for Pregnant Patients with Sickle Cell Disease and Prior DVT

Rationale for LMWH Selection

Sickle cell disease is a maternal disease risk factor that warrants consideration of postpartum prophylaxis, according to the American Society of Hematology 1, 2, 3, 4

The American College of Obstetricians and Gynecologists recommends continuing LMWH for 6 weeks postpartum as the standard duration for patients with prior VTE and sickle cell disease 1, 2, 3, 4
Prophylaxis duration of 6 weeks is recommended across multiple international guidelines, including the American Society of Hematology, to reduce the risk of recurrent VTE 1, 2, 3, 4

Warfarin is contraindicated during pregnancy due to teratogenicity, and can only be considered postpartum during breastfeeding, according to the American College of Chest Physicians 4
Low-Dose Aspirin is insufficient for VTE prophylaxis in high-risk patients, and does not provide adequate protection against recurrent VTE, as stated by the American Heart Association 3
Elastic Stockings alone are inadequate for patients with prior VTE and additional risk factors, and may be used as adjunctive therapy but cannot replace pharmacologic prophylaxis, according to the American Society of Hematology 1, 2, 4